Developing new, effective vaccine against tuberculosis represents an important global health imperative. WHO calls for a strengthening of this effort. The PPCs for the development of tuberculosis vaccines targeting adolescents and adults, neonates and infants, as presented here, are offered to help guide this important and challenging initiative.

*Lewis K Schrager, Padmapriyadarsini Chandrasekaran, Bernard H Fritzell, Mark Hatherill, Paul-Henri Lambert, Helen McShane, Nadia Tornieporth, *Johan Vekemans*
WHO Initiative for Vaccine Research. Geneva, Switzerland (LS); National Institute of Research in Tuberculosis, India (PC); Tuberculosis Vaccine Initiative, Netherlands (BF); South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa (MH); University of Geneva, Geneva, Switzerland (P-HL); Hannover University of Applied Science and Arts, Hannover, Germany (NT); and WHO, Geneva, Switzerland (JV)
johan.vekemans@gmail.com

This work was supported by a grant from the Bill and Melinda Gates Foundation [OPP1160685]. NT holds Sanofi shares and stock options. MH and HM are investigators on specific tuberculosis vaccine candidate studies. All other authors declare no competing interests.

1 WHO. Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
2 Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015. *Vaccine* 2016; **34:** 2865–69.
3 WHO. Tuberculosis vaccine development. http://www.who.int/immunization/research/development/tuberculosis/en/ (accessed July 10, 2018).
4 Knight GM, Griffiths UK, Sumner T, et al. Impact and cost effectiveness of new tuberculosis vaccines in low- and middle-income countries. *Proc Natl Acad Sci USA* 2014; **111:** 15520–25.
5 Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. *Hum Vaccin Immunother*. 2016; **12:** 2813–32.
6 Poyntz HC, Stylianou E, Griffiths KL, Marsay L, Checkley AM, McShane H. Non-tuberculous mycobacteria have diverse effects on BCG efficacy against *Mycobacterium tuberculosis*. *Tuberculosis* 2014; **94:** 226–37.

Corrections

Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study. Lancet Infect Dis *2017;* ***17:*** *174–83*—In this Article, the copyright line should have been "© 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license." This correction has been made to the online version as of June 12, 2018.

Published **Online**
June 12, 2018
http://dx.doi.org/10.1016/S1473-3099(18)30396-7

Llanos-Cuentas A, Casapia M, Chuquiyauri R, et al. Antimalarial activity of single-dose DSM265, a novel Plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum *or* Plasmodium vivax *malaria infection: a proof-of-concept, open-label, phase 2a study.* Lancet Infect Dis *2018;* ***18:*** *874–83*—the open access license of this Article has been corrected to a Gold CC BY license. This correction has been made to the online version as of June 18, 2018, and will be made to the printed Article.

Published **Online**
June 18, 2018
http://dx.doi.org/10.1016/S1473-3099(18)30412-2

Chan XHS, Win YN, Mawer LJ, et al. Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis *2018;* ***18:*** *913–23*—In figure 3 on page 8 of the results section in this Article, the y-axis label for the middle graph should be 'Deaths within 30 days from dihydroartemisinin—piperaquine administration'. Additionally, the drug name in the title for table 2 should be 'dihydroartemisinin–piperaquine', and the author name for reference 27 should be 'Stan Development Team.' These corrections have been made to the online version as of June 26, 2018.

Published **Online**
June 26, 2018
http://dx.doi.org/10.1016/S1473-3099(18)30419-5